Last reviewed · How we verify

Shionogi & Co. — Portfolio Competitive Intelligence Brief

Shionogi & Co. (4507.T) pipeline: 5 marketed, 0 filed, 7 Phase 3, 9 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

4507.T (TSE) 5 marketed 0 filed 7 Phase 3 9 Phase 2 12 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fetroja CEFIDEROCOL marketed Cephalosporin Antibacterial Infectious Disease 2019-01-01
Ulesfia BENZYL ALCOHOL marketed Pediculicide [EPC] Dermatology 2009-01-01
Doribax DORIPENEM marketed Penem Antibacterial Infectious Disease 2007-01-01
Keflex cefalexin marketed Cephalosporin Antibacterial Solute carrier family 15 member 2 Metabolic 1971-01-01
Cuvposa GLYCOPYRRONIUM BROMIDE marketed Anticholinergic Muscarinic acetylcholine receptor M1 Metabolic 1961-01-01
Nonhormonal vaginal lubricant Nonhormonal vaginal lubricant phase 3 Women's Health
S-268019-b S-268019-b phase 3 5-HT4 receptor partial agonist 5-HT4 receptor Gastroenterology
Ospemifene (Dose 1) Ospemifene (Dose 1) phase 3 Selective estrogen receptor modulator (SERM) Estrogen receptor (ER-α and ER-β) Women's Health / Gynecology
S-217622 S-217622 phase 3 SGLT2 inhibitor SGLT2 Diabetes
Placebo to Baloxavir Marboxil Placebo to Baloxavir Marboxil phase 3 Cap-dependent endonuclease inhibitor Influenza virus PA endonuclease (cap-dependent endonuclease) Infectious Disease / Virology
Oral Glycopyrrolate Liquid Oral Glycopyrrolate Liquid phase 3 Anticholinergic Muscarinic acetylcholine receptor Respiratory
Pravafen Pravafen phase 3 Other

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 2 shared drug classes
  2. Shandong Suncadia Medicine Co., Ltd. · 2 shared drug classes
  3. Ain Shams University · 2 shared drug classes
  4. Astellas Pharma Inc · 2 shared drug classes
  5. AbbVie · 2 shared drug classes
  6. Sanofi · 2 shared drug classes
  7. · 2 shared drug classes
  8. Abbott · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Shionogi & Co.:

Cite this brief

Drug Landscape (2026). Shionogi & Co. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/shionogi. Accessed 2026-06-10.

Related